Eagle Pharmaceuticals, Inc.
EGRX
EGRX was delisted on the 2nd of October, 2024.
120 hedge funds and large institutions have $1.08B invested in Eagle Pharmaceuticals, Inc. in 2015 Q2 according to their latest regulatory filings, with 62 funds opening new positions, 29 increasing their positions, 26 reducing their positions, and 10 closing their positions.
520% more first-time investments, than exits
New positions opened: 62 | Existing positions closed: 10
121% more capital invested
Capital invested by funds: $489M → $1.08B (+$592M)
76% more funds holding
Funds holding: 68 → 120 (+52)
20% more funds holding in top 10
Funds holding in top 10: 5 → 6 (+1)
12% more repeat investments, than reductions
Existing positions increased: 29 | Existing positions reduced: 26
75% less call options, than puts
Call options by funds: $1.36M | Put options by funds: $5.5M
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
RIM
Ranger Investment Management
Dallas,
Texas
|
+$29.7M |
| 2 |
CCM
Consonance Capital Management
New York
|
+$29.1M |
| 3 |
State Street
Boston,
Massachusetts
|
+$28.1M |
| 4 |
PA
Perceptive Advisors
New York
|
+$14.4M |
| 5 |
BFA
BlackRock Fund Advisors
San Francisco,
California
|
+$12.8M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
CAM
Cormorant Asset Management
Boston,
Massachusetts
|
-$27.1M |
| 2 |
GE
General Electric
Evendale,
Ohio
|
-$25.2M |
| 3 |
Morgan Stanley
New York
|
-$11.2M |
| 4 |
PWAM
Park West Asset Management
San Francisco,
California
|
-$7.9M |
| 5 |
EI
EAM Investors
Solana Beach,
California
|
-$5.02M |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
|
BPC
126
Banque Pictet & Cie
Geneva 73,
Switzerland
| – | -$250K | -5,958 | Closed |
|
127
Bank of Montreal
Toronto,
Ontario, Canada
| – | -$80K | -1,908 | Closed |
|
128
Creative Planning
Overland Park,
Kansas
| – | -$18K | -426 | Closed |
|
|
TRCT
129
Tower Research Capital (TRC)
New York
| – | -$5K | -126 | Closed |
|
|
GC
130
Globeflex Capital
San Diego,
California
| – | +$261 | +4 | New |
|
EGRX Hedge Fund Activity: Q2 2015 in Review
120 of the 3,712 institutional investors tracked by Wall St. Rank reported a position in Eagle Pharmaceuticals, Inc. (EGRX) for Q2 2015, worth a combined $1.08B — up 121% from $489M a quarter earlier.
Buyers outnumbered sellers: 62 funds opened new EGRX positions and 10 closed out — a net gain of 52 holders — while 29 added to existing stakes and 26 trimmed.
The largest buyer was Ranger Investment Management, opening a new position worth an estimated $29.7M. The largest seller was Cormorant Asset Management, cutting an estimated $27.1M.
- 120 institutional investors held Eagle Pharmaceuticals, Inc. (EGRX) as of Q2 2015, up from 68 in Q1 2015.
- Funds reported $1.08B of Eagle Pharmaceuticals, Inc. stock for Q2 2015, up 121% quarter-over-quarter.
- 62 funds opened new Eagle Pharmaceuticals, Inc. positions in Q2 2015 and 10 closed out, a net change of +52 holders.
- The largest Eagle Pharmaceuticals, Inc. buyer in Q2 2015 was Ranger Investment Management, an estimated $29.7M added.
- The largest Eagle Pharmaceuticals, Inc. seller in Q2 2015 was Cormorant Asset Management, an estimated $27.1M sold.
Based on aggregated 13F filings for Q2 2015.